Bioreductive agents: A clinical update

Oncology Research

Volumn 9, Issue 6-7, 1997, Pages 391-395

  Boyer, Michael J ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Bioreduction; EO9; Hypoxia; Mitomycin; Tirapazamine

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTINEOPLASTIC AGENT; AZIRIDINE DERIVATIVE; INDOLE DERIVATIVE; MITOMYCIN; TIRAPAZAMINE; TRIAZINE DERIVATIVE;

BIOTRANSFORMATION; CLINICAL TRIAL; HUMAN; OXIDATION REDUCTION REACTION; REVIEW;

ANTINEOPLASTIC AGENTS; AZIRIDINES; BIOTRANSFORMATION; CLINICAL TRIALS; HUMANS; INDOLEQUINONES; INDOLES; MITOMYCIN; OXIDATION-REDUCTION; TRIAZINES;

EID: 0031297958     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: A review. Cancer Res. 49:6449-6465; 1989.
2. Gullino, P. M.; Grantham, F. H.; Smith, S. H.; Haggerty, A. C. Modifications of the acid-base status of the internal milieu of tumors. J. Natl. Cancer Inst. 34:857-869; 1965.
3. Tannock I; Boyer, M. J.; Karuri, A.; Maidorn, R.; Newell, K. J. Prospects for drugs exploiting lower tumor pH. In: Dewey, W. C.; Edington, M.; Fry, R. J. M.; Hall, E. J.; Whitmore, G. F., eds. Radiation research: A twentiethcentury perspective. San Diego: Academic Press; 1992:813-818.
4. Brown, J. M.; Koong, A. Therapeutic advantage of hypoxic cells in tumors: A theoretical study. J. Natl. Cancer Inst. 83: 178-185; 1991.
5. Tannock, 1. F. Oxygen diffusion and the distribution of cellular radiosensitivity in tumours. Br. J. Radio). 45:515-524; 1972.
6. Höckel, M.; Knoop, C.; Schlenger, K.; Vorndran, B.; Baubmann, E.; Mitze, M.; Knapstein, P. G.; Vaupel, P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26:45-50; 1993.
7. Vaupel, P.; Okunieff, P.; Kallinowski, F.; Neuringer, L. J. Correlations between 3IP-NMR spectroscopy and tissue O2 tension measurements in a murine fibrosarcoma. Radial. Res. 120:477-493; 1989.
8. Crooke, S. T.; Bradner, W. T. Mitomycin C: A review. Cancer Treat. Rev. 3:121-129; 1976.
9. Flam, M.; John, M.; Pajak, T. F.; Petrelli, N.; Myerson, R.; Doggett, S.; Quivey, J.; Rotman, M.; Kerman, H.; Coia, L.; Murray, K. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J. Clin. Oncol. 14:2527-2539; 1996.
10. Haffty, B. G.; Son, Y. H.; Papac, R.; Sasaki, C. T.; Weissberg, J. B.; Fischer, D.; Rockwell, S.; Sartorelli, A. C.; Fischer, J. J. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials. J. Clin. Oncol. 15:268-276; 1997.
11. Hendricks, H. R.; Pizao, P. E.; Berger, D. P. EO9: A novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur. J. Cancer. 29A:897-906; 1993.
12. Schellens, J. H. M.; Planting, A. S. T.; van Acker, B. A. C.; Loos, W. J.; de Boer-Dennert, M.; van der Burg, M. E. L.; Koier, I.; Krediet, R. T.; Stoter, G.; Verweij, J. Phase I and pharmacologie study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J. Natl. Cancer Inst. 86:906-912; 1994.
13. Pavlidis, N.; Hanauske, A.R.; Gamucci, T.; Smyth, J.; Lehnen, M.; te Velde, A.; Lan, J.; Verweij, J. A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small cell lung cancer: A study of the EORTC Early Clinical Studies Group. Ann. Oncol. 7:529-531; 1996.
14. Dirix, L. Y.; Tonnesen, F.; Cassidy, J.; Epelbaum, R.; Huinink, W. W. T.; Pavlidis, N.; Sorio, R.; Gamucci, T.; Wolff, I.; te Velde, A.; Lan, J.; Verweij, J. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur. J. Cancer 32A:20I9-2022; 1996.
15. Brown, J. M. SR4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 67:1163-1170; 1993.
16. Zeman, E. M.; Brown, J. M.; Lemmon, M. J.; Hirst, V. K.; Lee, W. W. SR4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiât. Oncol. Biol. Phys. 12:1239-1242; 1986.
17. Stratford, I. J.; Stephens, M. A. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Radial. Oncol. Biol. Phys. 16:973-976; 1989.
18. Adams, G. E.; Stratford, I. J.; Edwards, H. S.; Bremner, J. C. M.; Coles, S. Bioreductive drugs as post-irradiation sensitizers: Comparison of dual function agents with SR4233 and the mitomycin C analogue EO9. Int. J. Radiât. Oncol. Biol. Phys. 22:717-720; 1992.
19. Brown, J. M.; Lemmon, M. J. Potentiation by the hypoxic cytotoxin SR4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 50:7745-7749; 1990.
20. Shulman, L.; Coleman, C. N.; Buswell, L.; Riese, N.; Doherty, N.; O'Neil, N.; Roemeling, R. A phase I study of multiple dose tirapazamine (TIRA, SR4233) given concurrently with radiation therapy (RT) [Abstract]. Proc. Am. Soc. Clin. Oncol. 14:1534 1995.
21. Hancock, S. L.; Mariscal, C.; Marquez, C.; Spiegel, J. F.; von Roemeling, R.; Bradley, E.; Brown, J. M. A phase I trial of single dose tirapazamine with radiation therapy for advanced malignancies: Tolerance and pharmacokinetics of a novel hypoxic cell cytotoxin [Abstract]. Proc. Am. Soc. Clin. Oncol. 13:405 1994.
22. Holden, S. A.; Teicher, B. A.; Ara, G.; Herman, T. S.; Coleman, C. N. Enhancement of alkylating agent activity by SR4233 in thé FSalIC murine fibrosarcoma. J. Natl. Cancer Inst. 84:187-193; 1992.
23. Dorie, M. J.; Brown, J. M. Tumor-specific, scheduledependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res. 53:4633-4636; 1993.
24. Lartigau, E.; Guichard, M. The effect of tirapazamine (SR4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Br. J. Cancer 73:1480-1485; 19%.
25. Johnson, C. A.; Kilpatrick, D.; von Roemeling, R.; Langer, C.; Graham, M. A.; Greenslade, D.; Kennedy, G.; Keenan, E.; O'Dwyer, P. J. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J. Clin. Oncol. 15:773-780; 1997.
26. Rodriguez, G. I.; Valdivieso, M.; Von Hoff, D. D.; Kraut, M.; Burris, H. A.; Eckardt, J. R.; Lockwood, G.; Kennedy, H.; von Roemeling, R. A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer [Abstract]. Proc. Am. Soc. Clin. Oncol. 15:1144 1996.
27. Aghajanian, C.; Fennelly, D.; Shapiro, F.; Fleischauer, A.; Brown, C.; Curtin, J.; Spriggs, D. R. Phase I trial of tirapazamine (WIN 59075; SR4233) plus cisplatin in cervical cancer [Abstract]. Proc. Am. Soc. Clin. Oncol. 15:825 1996.
28. Treat, J.; Greenberg, R.; Rodriguez, R.; Drobins, P.; Miller, W.; Meehan, J.; Neefe, J.; von Roemeling, R. Tirapazamine with cisplatin: Phase II in advanced stage non small cell cancer (NSCLC) [Abstract]. Proc. Am. Soc. Clin. Oncol. 15:1216 1996.
29. Miller, V. A.; Pizzo, B.; Grant, S. C.; Heelan, R. T.; von Roemeling, R. Phase 11 study of tirapazamine, a unique bioreductive agent, with cisplatin in patients with advanced nonsmall cell lung cancer (NSCLC) [Abstract]. Proc. Am. Soc. Clin. Oncol. 15:1228 1996.
30. Bedikian, A. Y.; Legha, S. S.; Buzaid, A. C.; Eton, O.; Papadopoulos, N.; Coates, S.; Simmons, T.; von Roemeling, R. Phase II trial of tirapazamine plus cisplatin in patients with advanced melanoma [Abstract]. Proc. Am. Soc. Clin. Oncol. 15:1345 1996.
31. Ara, G.; Coleman, C. N.; Teicher, B. A. SR-4233 (tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells. Cancer Lett. 85:195-203; 1994.
32. Koh, W. J.; Bergman, K. S.; Rasey, J. S.; Peterson, L. M.; Evans, M. L.; Graham, M. M.; Grierson, J. R.; Lindsley, K. L.; Lewellen, T. K.; Krohn, K. A.; et al. Evaluation of oxygénation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int. J. Radiât. Oncol. Biol. Phys. 33:391-398; 1995.
33. Yang, D. J.; Wallace, S.; Cherif, A.; Li, C.; Gretzer, M. B.; Kim, E. E.; Podoloff, D. A. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 194:795-800; 1995.